Key result
Administration of the HDAC inhibitor SAHA to DOCA-salt hypertensive rats attenuated cardiovascular remodelling, including cardiac fibrosis, left ventricular hypertrophy, and systolic hypertension.
Why the study?
Does the HDAC inhibitor SAHA prevent cardiac fibrosis and cardiovascular remodeling in DOCA-salt hypertensive rats?
Population
Deoxycorticosterone acetate (DOCA)-salt hypertensive rats and control rats
Comparison
Suberoylanilide hydroxamic acid 25 mg/kg/day… vs Untreated DOCA-salt rats and control rats
Design
Preclinical
Follow-up
32 days
Authors
Loading...
SAHA attenuated fibrosis in this model; leaves open whether HDAC inhibition affects human cardiac remodelling.
Does the HDAC inhibitor SAHA prevent cardiac fibrosis and cardiovascular remodeling in DOCA-salt hypertensive rats?
The broad-spectrum HDAC inhibitor SAHA attenuates cardiovascular remodeling, particularly cardiac fibrosis, in a rat model of hypertension, suggesting a potential therapeutic approach.
Iyer et al. (2010) studied DOCA-salt hypertension. Suberoylanilide hydroxamic acid (SAHA) vs. Control was evaluated on Cardiovascular structure and function, and left ventricular collagen deposition. Administration of the HDAC inhibitor SAHA to DOCA-salt hypertensive rats attenuated cardiovascular remodelling, including cardiac fibrosis, left ventricular hypertrophy, and systolic hypertension.